The objective of this study is to evaluate the safety and efficacy of subcutaneous Betaseron in AIDS and advanced ARC patients receiving a reduced dose AZT regimen because they are intolerant of a full dose AZT treatment. It will also determine if administration of daily subcutaneous Betaseron can reduce the morbidity and mortality of these patients.
Showing the most recent 10 out of 470 publications